FTFrancesca Tucci

Francesca Tucci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesca Tucci has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • How Does Hematopoietic Stem Cell Gene Therapy Affect Hip Dysplasia in Mucopolysaccharidosis Type I Hurler Syndrome? Radiological Outcomes at a Minimum 4-year Follow-up

    by Maurizio De Pellegrin, Matilde Cossutta, Giulia Consiglieri, Francesca Contisciani, Chiara Filisetti, Francesca Tucci, Camilla Morosini, Renata Mellone, Simone Romeni, Alessandro Aiuti, et al.

    Background: Mucopolysaccharidosis type I (MPS IH), or Hurler syndrome, is a lysosomal disorder caused by glycosaminoglycan accumulation due to an α-L-iduronidase deficiency. It is characterized by progressive skeletal impairment and impaired cognitive development. Hip dysplasia is a major skeletal manifestation for which conventional treatments (allogeneic hematopoietic stem cell transplantation with or without enzyme replacement therapy) does not prevent progression. Questions/purposes: Among patients with MPS IH, does hematopoietic stem cell gene therapy (HSC-GT) result in (1) longitudinal improvement in bony measurements of hip dysplasia, specifically the acetabular index (the angle between the Hilgenreiner line and the line drawn from the Y-cartilage to the lateral edge of the acetabular roof) and migration percentage (the proportion of the femoral head lateral to a Perkins line drawn from the lateral edge of the acetabular roof); (2) improvement in the cartilaginous acetabular index and migration percentage, accounting for the cartilaginous components of the acetabular roof and femoral head; and (3) an increase in the proportion of patients with an acetabular index and cartilaginous acetabular index within published norms? Methods: Between 2018 and 2019, 8 patients (6 males, 2 females) with MPS IH received OTL-203, an HSC-GT, in a Phase I/II clinical trial. All patients met the trial eligibility criteria, including absence of a suitable allogeneic donor and a Developmental Quotient or Intelligence Quotient score ≥ 70. Median (range) age at treatment was 23.5 months (14 to 34). All patients had dysplastic hip morphology at baseline, with abnormal acetabular index values and reduced femoral head coverage. This secondary analysis used prospectively collected orthopaedic and skeletal data from the same trial cohort, including hip radiographs and MRIs obtained during multidisciplinary follow-up. All patients completed the 5-year follow-up and entered the approved long-term follow-up program (up to 15 years after HSC-GT); no patients were lost to follow-up. One patient with pretreatment bilateral hip dislocation underwent hip surgery and was excluded from the subsequent longitudinal analysis, with radiological data retained up to surgery. One additional patient had missing radiographic assessments because behavioral difficulties precluded imaging; all other patients had 4-year assessments available. Hip dysplasia was assessed at baseline and 1, 2, 3, and 4 years after HSC-GT using acetabular index and migration percentage on radiographs and MRIs, as well as cartilaginous acetabular index and cartilaginous migration percentage on MRI. Radiological measurements were compared with published age- and sex-specific normative values. Mean ± SD age at last follow-up was 5.8 ± 0.5 years. Results: Radiographic acetabular index and migration percentage decreased longitudinally (acetabular index: fixed effect estimate = -2.7° per year [95% CI -3.5° to -1.9°]; p < 0.001; migration percentage: fixed effect estimate = -8.1% per year [95% CI -9.8% to -6.3%]; p < 0.001). MRI acetabular index, migration percentage, and cartilaginous acetabular index decreased longitudinally (acetabular index: fixed effect estimate = -2.2° per year [95% CI -3.1° to -1.2°]; p < 0.001; migration percentage: fixed effect estimate = -2.6% per year [95% CI -4.4% to -0.9%]; p = 0.003; cartilaginous acetabular index: fixed effect estimate = -0.8° per year [95% CI -1.6° to -0.1°]; p = 0.02). However, there was no overall longitudinal change in cartilaginous migration percentage when all timepoints were considered (fixed effect estimate = -0.8% per year [95% CI -1.8% to 0.3%]; p = 0.15). The proportion of hips with acetabular measurements within published normative ranges increased during follow-up: acetabular index consistent with hip dysplasia decreased from 12 of 14 hips at baseline to 6 of 12 hips at 4 years, and severe hip dysplasia decreased from 11 of 14 hips to 1 of 12 hips within the same time frame. MRI measurements showed a similar shift toward published normative values from individuals without MPS IH. Radiographic and MRI measurements were positively correlated across examinations obtained at the same timepoints (acetabular index: r = 0.61 [95% CI 0.42 to 0.75]; p < 0.001; migration percentage: r = 0.54 [95% CI 0.32 to 0.70]; p < 0.001). Variations between baseline and 4-year follow-up in bony and cartilaginous measurements were also positively correlated (acetabular index and cartilaginous acetabular index: r = 0.53 [95% CI 0.001 to 0.83]; p = 0.05; migration percentage and cartilaginous femoral head coverage: r = 0.61 [95% CI 0.06 to 0.88]; p = 0.03). Conclusion: These findings suggest that hip dysplasia may stabilize or improve after OTL-203 treatment, supporting continued radiological surveillance in young children after HSC-GT. Longer-term prospective multicenter studies are needed to assess durability and clinical relevance and to compare outcomes with bone marrow transplantation. Level of Evidence: Level IV, therapeutic study.

  • Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome

    by Giulia Consiglieri, Francesca Tucci, Maurizio De Pellegrin, Barbara Guerrini, Alessandro Cattoni, Giulia Risca, Stefano Scarparo, Marina Sarzana, Silvia Pontesilli, Renata Mellone, et al.

    Mucopolysaccharidosis type I Hurler (MPSIH) is characterized by severe and progressive skeletal dysplasia that is not fully addressed by allogeneic hematopoietic stem cell transplantation (HSCT). Autologous hematopoietic stem progenitor cell–gene therapy (HSPC-GT) provides superior metabolic correction in patients with MPSIH compared with HSCT; however, its ability to affect skeletal manifestations is unknown. Eight patients with MPSIH (mean age at treatment: 1.9 years) received lentiviral-based HSPC-GT in a phase 1/2 clinical trial (NCT03488394). Clinical (growth, measures of kyphosis and genu velgum), functional (motor function, joint range of motion), and radiological [acetabular index (AI), migration percentage (MP) in hip x-rays and MRIs and spine MRI score] parameters of skeletal dysplasia were evaluated at baseline and multiple time points up to 4 years after treatment. Specific skeletal measures were retrospectively compared with an external cohort of HSCT-treated patients. At a median follow-up of 3.78 years after HSPC-GT, all patients treated with HSPC-GT exhibited longitudinal growth within WHO reference ranges and a median height gain greater than that observed in patients treated with HSCT after 3-year follow-up. Patients receiving HSPC-GT experienced complete and earlier normalization of joint mobility compared with patients treated with HSCT. Mean AI and MP showed progressive decreases after HSPC-GT, suggesting a reduction in acetabular dysplasia. Typical spine alterations measured through a spine MRI score stabilized after HSPC-GT. Clinical, functional, and radiological measures suggested an early beneficial effect of HSPC-GT on MPSIH-typical skeletal features. Longer follow-up is needed to draw definitive conclusions on HSPC-GT’s impact on MPSIH skeletal dysplasia.


  • Open Access

    Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series

    by Daniele Canarutto, Chiara Oltolini, Federica Barzaghi, Valeria Calbi, Maddalena Migliavacca, Francesca Tucci, Vera Gallo, Giulia Consiglieri, Francesca Ferrua, Salvatore Recupero, et al.

    Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.


  • Evidence of Treatment Benefits in Patients with Mucopolysaccharidosis Type I-Hurler in Long-term Follow-up Using a New Magnetic Resonance Imaging Scoring System

    by Silvia Pontesilli, Cristina Baldoli, Pasquale Anthony Della Rosa, Alessandro Cattoni, Maria Ester Bernardo, Pamela Meregalli, Serena Gasperini, Serena Motta, Francesca Fumagalli, Francesca Tucci, et al.


  • Open Access

    Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

    by Bernhard Gentner, Maria Ester Bernardo, Francesca Tucci, Erika Zonari, Francesca Fumagalli, Silvia Pontesilli, Serena Acquati, Paolo Silvani, Fabio Ciceri, Attilio Rovelli, et al.

    Allogeneic hematopoietic stem cell transplantation (HSCT) performed early in life is the current standard of care for patients with severe type 1 mucopolysaccharidosis (Hurler disease), a metabolic disorder caused by mutations in the alpha-L-iduronidase (IDUA) gene, leading to impaired breakdown of glycosaminoglycans (GAG). Secretion of IDUA by donor-derived hematopoietic cells may cross-correct non-hematopoietic cells, slowing progression of tissue damage and cognitive decline. Nevertheless, Hurler patients undergoing HSCT manifest substantial residual disease burden, e.g. on the skeleton and central nervous system (CNS). We conducted a phase I/II clinical study (NCT03488394) to test whether infusion of autologous CD34+ hematopoietic stem and progenitor cells (HSPC) transduced ex vivo with a lentiviral vector coding for the IDUA gene was feasible, safe and capable of restoring enzymatic activity in the patients' blood and tissues, up to supraphysiologic levels. The trial originally planned to enroll 6 Hurler patients with preserved neurocognitive function (DQ/IQ>70) that had no access to a suitable allogeneic donor. Sample size has recently been increased to 8 patients. By July 2019, six patients have been treated at a median age of 24 months (range: 14-34), with a median follow up of 4 months (range: 1-13). In all patients, we collected a high number of autologous HSPC by leukapheresis following mobilization with lenograstim and plerixafor, resulting in drug products with a median of 21 million CD34+ cells/kg (range: 13-29). Transduction efficiency was high with a median above 80% and a vector copy number (VCN) of 1.7 (range: 1.0-5.2), employing a shortened, 2 day transduction protocol that included prostaglandin E2. All patients showed rapid hematopoietic recovery following myeloablative conditioning with busulfan (targeted to an AUC of 80mg*h/L), fludarabine (160mg/sqm) and rituximab (375mg/sqm). Median duration of grade 4 neutropenia associated with conditioning was 15.5 days (range: 13-19). Also associated with conditioning, Grade 3 thrombocytopenia lasted 4 days, while only 2 out of 6 patients experienced a platelet drop below 20,000/mcL on a single day, in the absence of transfusion support. Adverse events were mild and compatible with myeloablative conditioning, with the exception of patient 3 who experienced an anaphylactic reaction on day+12, which promptly responded to antihistamines, IV fluids and steroids. All evaluable patients showed sustained, supraphysiologic blood IDUA activity (dried blood spot), which was on average 3 fold above the upper limit of normal (evaluable patients: n=5 at 1 month, n=4 at 2 months, n=3 at 3 months). Notably, in n=4 Hurler patients treated with allogeneic HSCT, we detected IDUA activity that ranged within the lowest quartile of normal in spite of full donor chimerism, suggesting substantial gain achieved by overexpressing IDUA in ex vivo genetically-modified autologous HSPC. Urinary GAG excretion fell to normal levels within 3-6 months. IDUA activity was also detected in the cerebrospinal fluid (CSF) of treated patients, accompanied by a logfold reduction in CSF GAGs in the 2 patients with longest follow up. This suggests that gene therapy accomplishes full metabolic correction of tissues, including the CNS. Gene therapy did not induce antibodies against the IDUA protein, while pre-existing antibodies induced by enzyme replacement therapy before gene therapy rapidly disappeared. Patient 1 who reached the 1-year follow-up demonstrated a stable cognitive score, improved findings on brain and spine MRI, resumed growth velocity and an improvement of his skeletal phenotype. The preliminary results from our phase I/II study compare favorably with the standard of care in terms of safety and efficacy, and highlight the potential of genetic engineering of HSPC grafts for therapeutic gain-of-function. Disclosures: Gentner: Genenta Science: Consultancy, Equity Ownership, Research Funding. Parini:Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Financial Support; BioMarin: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Financial Support; Ultragenyx: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Financial Support; SOBI: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Financial Support; Orphan Europe: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Financial Support; Sanofi-Genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Financial Support. Naldini:San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), a joint venture between Fondazione Telethon and Ospedale San Raffaele (OSR): Other: Wiskott-Aldrich Syndrome (WAS) gene therapy was licensed to GlaxoSmithKline (GSK) in 2014. It was then licensed to Orchard Therapeutics (OTL) in April 2018. OTL is the current sponsor of the clinical trial.; Genenta Science: Consultancy, Equity Ownership; Magenta Therapeutics: Equity Ownership. Aiuti:San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), a joint venture between Fondazione Telethon and Ospedale San Raffaele (OSR): Other: Wiskott-Aldrich Syndrome (WAS) gene therapy was licensed to GlaxoSmithKline (GSK) in 2014. It was than licensed to Orchard Therapeutics (OTL) in April 2018. OTL is the current sponsor of the clinical trial.; San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), a joint venture between Fondazione Telethon and Ospedale San Raffaele (OSR): Other: Study PI.


  • Open Access

    Bone marrow harvesting from paediatric patients undergoing haematopoietic stem cell gene therapy

    by Francesca Tucci, Marta Frittoli, Federica Barzaghi, Valeria Calbi, Maddalena Migliavacca, Francesca Ferrua, Francesca Fumagalli, Laura Lorioli, Laura Castagnaro, Marcella Facchini, et al.

    Collection of an adequate amount of autologous haematopoietic stem progenitor cells (HSPC) is required for ex vivo manipulation and successful engraftment for certain inherited disorders. Fifty-seven paediatric patients (age 0.5–11.4 years) underwent a bone marrow harvest for the purpose of HSPC gene therapy (GT), including adenosine deaminase-severe combined immunodeficiency (ADA-SCID), Wiskott–Aldrich syndrome (WAS) and metachromatic leukodystrophy (MLD) patients. Total nucleated cells and the percentage and absolute counts of CD34+ cells were calculated at defined steps of the procedure (harvest, CD34+ cell purification, transduction with the gene transfer vector and infusion of the medicinal product). A minimum CD34+ cell dose for infusion was 2 × 106/kg, with an optimal target at 5–10 × 106/kg. Median volume of bone marrow harvested was 34.2 ml/kg (range 14.2–56.6). The number of CD34+ cells collected correlated inversely with weight and age in all patients and particularly in the MLD children group. All patients reached the minimum target dose for infusion: median dose of CD34+ cells/kg infused was 10.3 × 106/kg (3.7–25.9), with no difference among the three groups. Bone marrow harvest of volumes > 30 ml/kg in infants and children with ADA-SCID, WAS and MLD is well tolerated and allows obtaining an adequate dose of a medicinal product for HSPC-GT.


  • Schiller e l'antico

    by Francesca Tucci